Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($) $ in Thousands |
May 10, 2021 |
Apr. 15, 2021 |
---|---|---|
Ampersand Note [Member] | ||
Debt instrument increase in note principle amount | $ 4,500 | |
Debt maturity date | Jun. 30, 2021 | |
Debt interest rate | 8.00% | |
1315 Capital Note [Member] | ||
Debt instrument increase in note principle amount | $ 3,000 | |
Debt maturity date | Jun. 30, 2021 | |
Debt interest rate | 8.00% | |
Security Agreement [Member] | ||
Debt instrument increase in note principle amount | $ 7,500 | |
Debt maturity date | Jun. 30, 2021 | |
Debt interest rate | 8.00% | |
DiamiR Biosciences, Corp. [Member] | ||
Disposal group description | Company closed the agreement to sell its New Haven, CT CLIA certified, CAP accredited laboratory to DiamiR Biosciences, Corp. ("DiamiR"). The agreement had been previously announced on March 17, 2021. Under the agreement, DiamiR will provide overflow lab testing in support of the Company's molecular thyroid testing products which the Company conducts at its main laboratory in Pittsburgh, PA. DiamiR will also support specific Interpace assay development and validation services on behalf of the Company for the next three quarters. The Company will receive 42,820 shares of DiamiR's common stock in consideration as well as the services mentioned above. |
X | ||||||||||
- Definition Net increase or decrease in the carrying amount of the debt instrument for the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Contractual interest rate for funds borrowed, under the debt agreement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Description of the facts and circumstances leading to the decision to change the plan to sell the disposal group, including discontinued operation, and its effect on the results of operations of the period and any prior periods presented. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|